跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 100 条关于
“sibeprenlimab-szsi”
全部
100
临床试验
76
药物
8
机构
0
资讯
16
9个月前
FDA Grants First Accelerated Approval for Novel IgA Nephropathy Treatment VOYXACT
3个月前
How a Rare Kidney Disease Gained a Robust New Therapy Pipeline
10个月前
Sibeprenlimab Demonstrates 54% Proteinuria Reduction in Largest Phase 3 IgA Nephropathy Trial
去年
Otsuka Submits BLA for Sibeprenlimab: A Novel Targeted Therapy for IgA Nephropathy
去年
Otsuka's Sibeprenlimab Shows Positive Phase 3 Interim Results for IgA Nephropathy
去年
Otsuka's Sibeprenlimab Achieves 51% Reduction in Proteinuria for IgA Nephropathy, Intensifying Competition with Vera Therapeutics
11个月前
Climb Bio's CLYM116 Shows Superior Performance in IgA Nephropathy Preclinical Study
去年
ERA 2025 to Feature Pivotal Nephrology Trials Including CONFIDENCE, ACHIEVE, and VISIONARY Studies
去年
Vera Therapeutics' Atacicept Achieves 46% Protein Reduction in Phase 3 IgA Nephropathy Trial
9个月前
Nephrology Advances in 2025: FDA Approvals and Clinical Breakthroughs Transform Kidney Disease Treatment
第 1 页,共 2 页
上一页
下一页